vs

Side-by-side financial comparison of EPR PROPERTIES (EPR) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $182.9M, roughly 1.8× EPR PROPERTIES). EPR PROPERTIES runs the higher net margin — 36.6% vs -18.2%, a 54.8% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 3.2%). EPR PROPERTIES produced more free cash flow last quarter ($269.2M vs $-133.8M).

EPR Properties, formerly Entertainment Properties Trust, is a real estate investment trust based in Kansas City, Missouri, that invests in amusement parks, movie theaters, ski resorts, and other entertainment properties. It owns 353 properties as of 2022.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

EPR vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.8× larger
MDGL
$321.1M
$182.9M
EPR
Growing faster (revenue YoY)
MDGL
MDGL
+207.5% gap
MDGL
210.8%
3.2%
EPR
Higher net margin
EPR
EPR
54.8% more per $
EPR
36.6%
-18.2%
MDGL
More free cash flow
EPR
EPR
$403.1M more FCF
EPR
$269.2M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EPR
EPR
MDGL
MDGL
Revenue
$182.9M
$321.1M
Net Profit
$66.9M
$-58.6M
Gross Margin
Operating Margin
56.8%
-18.6%
Net Margin
36.6%
-18.2%
Revenue YoY
3.2%
210.8%
Net Profit YoY
897.0%
1.4%
EPS (diluted)
$0.80
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPR
EPR
MDGL
MDGL
Q4 25
$182.9M
$321.1M
Q3 25
$182.3M
$287.3M
Q2 25
$178.1M
$212.8M
Q1 25
$175.0M
$137.3M
Q4 24
$177.2M
$103.3M
Q3 24
$180.5M
$62.2M
Q2 24
$173.1M
Q1 24
$167.2M
$0
Net Profit
EPR
EPR
MDGL
MDGL
Q4 25
$66.9M
$-58.6M
Q3 25
$66.6M
$-114.2M
Q2 25
$75.6M
$-42.3M
Q1 25
$65.8M
$-73.2M
Q4 24
$-8.4M
$-59.4M
Q3 24
$46.6M
$-107.0M
Q2 24
$45.1M
Q1 24
$62.7M
$-147.5M
Gross Margin
EPR
EPR
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
EPR
EPR
MDGL
MDGL
Q4 25
56.8%
-18.6%
Q3 25
53.5%
-39.7%
Q2 25
62.5%
-22.2%
Q1 25
58.1%
-57.8%
Q4 24
25.5%
-64.8%
Q3 24
51.4%
-187.1%
Q2 24
45.9%
Q1 24
58.8%
Net Margin
EPR
EPR
MDGL
MDGL
Q4 25
36.6%
-18.2%
Q3 25
36.5%
-39.8%
Q2 25
42.5%
-19.9%
Q1 25
37.6%
-53.4%
Q4 24
-4.7%
-57.5%
Q3 24
25.8%
-172.0%
Q2 24
26.1%
Q1 24
37.5%
EPS (diluted)
EPR
EPR
MDGL
MDGL
Q4 25
$0.80
$-2.55
Q3 25
$0.79
$-5.08
Q2 25
$0.91
$-1.90
Q1 25
$0.78
$-3.32
Q4 24
$-0.19
$-2.50
Q3 24
$0.53
$-4.92
Q2 24
$0.51
Q1 24
$0.75
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPR
EPR
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$90.6M
$198.7M
Total DebtLower is stronger
$2.9B
$339.9M
Stockholders' EquityBook value
$2.3B
$602.7M
Total Assets
$5.7B
$1.3B
Debt / EquityLower = less leverage
1.26×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPR
EPR
MDGL
MDGL
Q4 25
$90.6M
$198.7M
Q3 25
$13.7M
$295.7M
Q2 25
$13.0M
$186.2M
Q1 25
$20.6M
$183.6M
Q4 24
$22.1M
$100.0M
Q3 24
$35.3M
$232.7M
Q2 24
$33.7M
Q1 24
$59.5M
$622.5M
Total Debt
EPR
EPR
MDGL
MDGL
Q4 25
$2.9B
$339.9M
Q3 25
$2.8B
$339.8M
Q2 25
$2.8B
$118.4M
Q1 25
$2.8B
$118.0M
Q4 24
$2.9B
$117.6M
Q3 24
$2.9B
$117.1M
Q2 24
$2.8B
Q1 24
$2.8B
$116.1M
Stockholders' Equity
EPR
EPR
MDGL
MDGL
Q4 25
$2.3B
$602.7M
Q3 25
$2.3B
$625.7M
Q2 25
$2.3B
$696.0M
Q1 25
$2.3B
$710.6M
Q4 24
$2.3B
$754.4M
Q3 24
$2.4B
$777.2M
Q2 24
$2.4B
Q1 24
$2.4B
$850.8M
Total Assets
EPR
EPR
MDGL
MDGL
Q4 25
$5.7B
$1.3B
Q3 25
$5.5B
$1.4B
Q2 25
$5.6B
$1.0B
Q1 25
$5.5B
$996.6M
Q4 24
$5.6B
$1.0B
Q3 24
$5.7B
$1.1B
Q2 24
$5.6B
Q1 24
$5.7B
$1.1B
Debt / Equity
EPR
EPR
MDGL
MDGL
Q4 25
1.26×
0.56×
Q3 25
1.19×
0.54×
Q2 25
1.20×
0.17×
Q1 25
1.20×
0.17×
Q4 24
1.23×
0.16×
Q3 24
1.19×
0.15×
Q2 24
1.16×
Q1 24
1.15×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPR
EPR
MDGL
MDGL
Operating Cash FlowLast quarter
$421.0M
$-133.5M
Free Cash FlowOCF − Capex
$269.2M
$-133.8M
FCF MarginFCF / Revenue
147.1%
-41.7%
Capex IntensityCapex / Revenue
82.9%
0.1%
Cash ConversionOCF / Net Profit
6.29×
TTM Free Cash FlowTrailing 4 quarters
$568.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPR
EPR
MDGL
MDGL
Q4 25
$421.0M
$-133.5M
Q3 25
$136.5M
$79.8M
Q2 25
$87.3M
$-47.1M
Q1 25
$99.4M
$-88.9M
Q4 24
$393.1M
$-104.5M
Q3 24
$122.0M
$-67.0M
Q2 24
$78.7M
Q1 24
$99.5M
$-149.2M
Free Cash Flow
EPR
EPR
MDGL
MDGL
Q4 25
$269.2M
$-133.8M
Q3 25
$132.1M
$79.0M
Q2 25
$82.4M
Q1 25
$84.7M
Q4 24
$129.2M
$-104.7M
Q3 24
$121.5M
$-67.8M
Q2 24
$71.3M
Q1 24
$65.0M
$-149.5M
FCF Margin
EPR
EPR
MDGL
MDGL
Q4 25
147.1%
-41.7%
Q3 25
72.5%
27.5%
Q2 25
46.3%
Q1 25
48.4%
Q4 24
72.9%
-101.3%
Q3 24
67.3%
-109.0%
Q2 24
41.2%
Q1 24
38.9%
Capex Intensity
EPR
EPR
MDGL
MDGL
Q4 25
82.9%
0.1%
Q3 25
2.4%
0.3%
Q2 25
2.7%
0.0%
Q1 25
8.4%
0.0%
Q4 24
148.9%
0.2%
Q3 24
0.3%
1.3%
Q2 24
4.2%
Q1 24
20.6%
Cash Conversion
EPR
EPR
MDGL
MDGL
Q4 25
6.29×
Q3 25
2.05×
Q2 25
1.15×
Q1 25
1.51×
Q4 24
Q3 24
2.62×
Q2 24
1.74×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPR
EPR

Experiential Reportable Operating Segment$173.3M95%
Education Reportable Operating Segment$9.5M5%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons